Engflag

Alfospas

Quick links to important sections

Alfospas

Alfospas_EN

Method of action: Drugs For Functional Gastrointestinal Disorders

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfospas

Property Description
Active ingredient Tiropramide Hydrochloride
Form Oral Tablet (Monotherapy)
Pharmacological class Synthetic Antispasmodic Agent
Common use Relief of spasmodic pain/colic
Origin Synthetic Tyrosine derivative

What Type of Medicine is Alfospas (Tiropramide)?

Alfospas is a pharmaceutical product containing the active compound Tiropramide Hydrochloride (INN: Tiropramide). It is classified as a synthetic antispasmodic agent and is typically supplied as an oral tablet for systemic use. Pharmacological studies have consistently confirmed the compound’s potent, direct action on smooth muscle tissue, which forms the basis for its therapeutic utility. The World Health Organization (WHO) ATC system groups Tiropramide with synthetic antispasmodics that feature tertiary amines.

Tiropramide is a synthetic derivative of tyrosine. Its classification within the antispasmodic category, supported by pharmacological studies, ensures a focused relief mechanism designed exclusively to counteract involuntary muscle contractions.

Composition and Form: Understanding its Myotropic Action

Alfospas functions as a potent smooth muscle relaxant primarily through myotropic action, directly affecting the muscle fibers of internal organs. The active ingredient, Tiropramide, works by modulating intracellular signaling pathways, specifically by inhibiting the phosphodiesterase enzyme and regulating calcium ion (Ca^2+) levels. Scientific literature confirms that this activity leads to effective smooth muscle relaxation. This unique, direct mechanism of action, well-documented in biochemical research, differentiates it from antispasmodics that primarily block nerve signals. As an oral tablet preparation, Alfospas is formulated for systemic delivery, ensuring its spasmolytic properties are efficiently distributed throughout the smooth muscle systems of the body.

Primary Purpose: Targeted Relief of Internal Muscle Spasms

The general therapeutic purpose of Alfospas is to provide targeted relief from the sharp, often debilitating pain associated with internal muscle spasms and colic. For example, it is commonly utilized in scenarios involving acute cramping or tension in organs of the digestive or urinary tracts, where the pain is mechanical in origin. By directly counteracting the excessive involuntary contractions, the drug’s intended action is to help restore a more normal muscular tone and function, thereby addressing the underlying cause of the spasmodic state. Its efficacy in managing such abdominal discomfort is recognized in clinical research.

What side effects are possible with Alfospas?

Possible Side Effects and Safety Information for Alfospas (Tiropramide)

Adverse Reaction Scope

The official safety profile for Alfospas (Tiropramide) classifies documented adverse reactions primarily into Common and Rare categories, consistent with regulatory guidelines. Effects are grouped by the major System-Organ Classes affected, primarily involving the Gastrointestinal and Nervous Systems.

Common Adverse Reactions: Non-serious side effects frequently listed in regulatory documents include dizziness, headache, fatigue, and gastrointestinal disturbances such as nausea, vomiting, constipation, and dry mouth. Gastrointestinal discomfort may appear shortly after taking the medication, aligning with time-related patterns noted in the official safety profile.

Serious Adverse Reactions: The label documents rare but clinically significant adverse reactions, including severe hypersensitivity or allergic reactions (such as swelling of the face and rash), and the potential for liver function abnormalities, especially with long-term use. The official safety data also notes a risk of severe symptoms in individuals with pre-existing cardiac conditions.

Safety-Related Restrictions and Considerations

The medicine is subject to Contraindications that prohibit its use in certain high-risk situations. This includes known hypersensitivity to Tiropramide, conditions involving gastrointestinal blockage (e.g., intestinal obstruction), and severe hepatic impairment. Official regulatory documents also advise that caution is required for patients with specific pre-existing conditions, such as Glaucoma or Prostatic Hypertrophy, as use may risk worsening the condition. Use during Pregnancy or Lactation is not recommended unless deemed necessary after an official risk/benefit assessment.

Overdose and Emergency Response

The regulatory guidance for Alfospas (Tiropramide Hydrochloride) overdose centers entirely on the need for immediate professional medical intervention. Official government labeling universally mandates that any individual who has suspected or confirmed ingestion of an amount significantly exceeding the prescribed dosage seek immediate medical attention. This is the primary and mandatory action required, irrespective of whether specific clinical manifestations are currently apparent.

The accessible regulatory documents do not explicitly detail specific, citable clinical signs, symptoms, or laboratory findings that define an overdose of Tiropramide. Due to this lack of an explicitly defined toxicological profile, the management approach is dictated by universal regulatory standards. The prescribing information confirms there is no specific antidote known for Tiropramide Hydrochloride overdose. As such, the established procedure for managing the exposure is to provide comprehensive symptomatic and supportive treatment.

This regulatory framework emphasizes that management of a potential overdose is not suitable for self-care. The profile prioritizes the procedural mandate of immediate professional assessment and potential hospitalization for necessary observation and supportive care. Patients are mandated to contact emergency services immediately if an overdose event is suspected.

Therapeutic Uses of Alfospas

Main Uses of Alfospas

Alfospas is a medication primarily used to manage symptoms associated with spasms in the smooth muscles of the digestive and biliary systems. Its main purpose is to alleviate discomfort by targeting the underlying muscle contractions that cause pain or cramping in the abdominal area.

Gastrointestinal Spasms

The medication is frequently utilized for the symptomatic relief of acute or chronic spasms within the gastrointestinal tract. This includes conditions where the muscles of the stomach or intestines contract involuntarily, leading to sensations of cramping, bloating, and localized pain.

Biliary Tract Disorders

Alfospas is also indicated for the management of spasms affecting the biliary system. It helps reduce tension in the bile ducts and gallbladder, which can be beneficial in addressing the discomfort associated with biliary colic or other functional disorders of the biliary tree.

Therapeutic Benefits

Targeted Muscle Relaxation

The primary benefit of Alfospas is its antispasmodic action. It works by relaxing the smooth muscles without significantly affecting normal physiological movements, such as regular intestinal peristalsis. This selectivity helps provide relief while minimizing disruptions to standard digestive processes.

Symptom Management

By reducing the frequency and intensity of muscle spasms, Alfospas contributes to the overall reduction of abdominal pain and cramping. This can lead to an improvement in the patient's comfort level and quality of life during episodes of digestive distress.

Functional Improvement

For individuals experiencing functional gastrointestinal disorders, the use of Alfospas can help stabilize the smooth muscle activity of the gut. This stabilization supports more predictable digestive function by mitigating the erratic contractions that often characterize these conditions.

Regulatory References

  1. NIH MedlinePlus guidance on Abdominal Spasm and Cramping

Eligibility and Restrictions for Use

Alfospas, whose active component is commonly Alverine Citrate, is generally intended for use in adults, including the elderly, for conditions involving smooth muscle spasm. The official regulatory documentation strictly defines specific populations who must avoid this medicine.

Contraindications and Non-Eligibility

The medicine is contraindicated and must not be used by individuals with certain serious pre-existing conditions. These include:

  • Intestinal obstruction (blockage of the gut).
  • Paralytic ileus (paralysis of the small bowel).
  • Known hypersensitivity or allergy to Alverine Citrate or any other ingredients in the formulation.

Use is not recommended for the following groups due to insufficient safety data or established restrictions:

  • Children below the age of 12 years.
  • Pregnant or breastfeeding individuals, as use is contraindicated or not recommended by various regulatory bodies due to limited evidence of safety in these physiological states.

Patients who are aged 40 years or over experiencing first-time symptoms, or who present with concerning signs such as passing blood from the bowel, fever, or unexplained weight loss, must consult a doctor immediately before use. This restriction ensures that the cause of symptoms is properly diagnosed before beginning treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Alfospas (Tiropramide Hydrochloride) is based on documented patterns related to the body's processing of the medicine and its functional effects on smooth muscle.

Documented Interaction Patterns

Category Interaction Statement (Regulatory-Aligned)
Pharmacokinetic (Exposure) Co-administration with enzyme inhibitors may potentially increase the plasma concentration of Tiropramide.
Conversely, enzyme inducers may potentially reduce the effectiveness of Tiropramide by increasing its metabolism and clearance.
Pharmacodynamic (Additive Effect) Concomitant use with other antispasmodic agents or anticholinergic agents may result in an additive smooth muscle-relaxant effect.

Contextual and Population Notes

The regulatory profile highlights specific considerations for product combinations and certain patient populations. While no drug-drug combinations are formally classified as contraindicated, the potential for additive effects with other smooth muscle relaxants is documented.

Official information notes that caution is required for patients with renal impairment or hepatic impairment, as these conditions can alter the drug's metabolism and excretion, thereby influencing systemic exposure.

Regarding substances, the official regulatory information for Tiropramide states that the interaction status with alcohol is formally recorded as unknown.

Mechanism of Action

Alfospas, which contains tiropramide, functions as a musculotropic agent with primary effects on the smooth muscle of the gastrointestinal tract and uterus. Its mechanism involves a dual interaction, centered on the cellular regulation of contraction.

First, tiropramide acts as an inhibitor of voltage-gated L-type calcium channels on the smooth muscle cell membrane. This molecular interaction reduces the transmembrane influx of extracellular calcium ions (Ca^2+) into the cytosol, which is essential for initiating the contractile cascade.

Second, tiropramide causes an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, potentially through the inhibition of phosphodiesterase (PDE) activity. The downstream cascade of elevated cAMP involves the activation of protein kinase A (PKA), which promotes the phosphorylation of myosin light-chain kinase (MLCK). This phosphorylation event inactivates MLCK, thereby reducing the phosphorylation of the myosin light chain.

The combined effect of reduced intracellular calcium and MLCK inactivation leads to a significant decrease in the formation of actin-myosin cross-bridges, resulting in a systemic physiological consequence of smooth muscle relaxation and modulation of enteric motility.

Dosage and Administration Information

How to Use Alfospas

Alfospas (Tiropramide Hydrochloride) is administered according to standardized regimens to ensure consistent and proper utilization. The instructions define the route, dosage, frequency, and conditions for its intake.

Dosing and Administration

Instruction Category Guideline/Rule
Route of Administration Primarily administered Orally as a film-coated tablet. Intravenous (IV) and Intramuscular (IM) injectable formulations are also recognized clinical routes for some products.
Standard Dosing Schedule The typical adult regimen specifies a single dose of 100 mg. This may be increased based on the prescribed regimen, with usage patterns suggesting up to 600 mg (e.g., 200 mg three times daily).
Frequency and Timing The standard oral administration pattern is a divided dose, taken two to three times per day. The dosing frequency is dictated by the specific therapeutic protocol.
Tablet Administration The tablet can be taken with or without food. It must be swallowed whole with water and should not be crushed, chewed, or broken to maintain its intended release profile.

Population and Procedural Constraints

The usage instructions also include specific constraints regarding patient populations and organ function:

  • Pediatric Use: The safety and effectiveness of Tiropramide have not been established for children under 12 years of age, restricting its use to older patients and adults.
  • Organ Impairment: Caution is advised, and dose adjustments may be required for patients with pre-existing hepatic or renal impairment.
  • Course Duration: Although often used for acute relief, administration in clinical trials for conditions involving spasms has been documented over courses lasting up to 4 weeks.

These administration guidelines dictate the high-level, standardized framework for the drug's use, defining the maximum daily exposure and required method of intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alfospas (Tiropramide)

Evidence for Use in Functional Gastrointestinal Spasms

The clinical evaluation of Tiropramide was studied for symptoms related to spasmodic pain and discomfort in the gastrointestinal system. Research was applied in studies examining patient-reported experiences in adults diagnosed with conditions like Irritable Bowel Syndrome (IBS). Research explored outcomes related to physical discomfort linked to involuntary muscle contractions and symptom variability in these patient populations.

Types of Clinical Trials and Outcomes Measured

The research was evaluated in several randomized controlled trials (RCTs) designed to monitor symptom change. These studies included double-blind, placebo-controlled trials, as well as larger active-controlled, non-inferiority trials comparing the medicine to another antispasmodic. A primary focus of the research was the severity of abdominal pain, measured using validated tools, alongside functional outcomes like changes in stool frequency and quality of life.

Evidence Regarding Long-Term Outcomes and Specific Populations

Research exploring short-term symptom changes used limited follow-up durations, typically around 4 weeks. Consequently, long-term effects are not fully established, and evidence about durability of response is limited to these primary controlled studies. The research was predominantly evaluated in specific groups of adult patients (20–75 years) diagnosed with IBS. Few data are available for pediatric patients (children) or the elderly, as these populations were generally excluded from the main trials.

What Remains Uncertain in the Clinical Research

The overall research is broadly classified as moderate evidence level. Key uncertainties include the limitations of the short follow-up durations. The design of the largest study was structured to assess comparability against an active medicine, meaning comprehensive evidence from large-scale studies against an inert substance (placebo) is limited. Scientific literature has previously noted that the overall research status of the compound was initially uncertain before these large-scale comparative studies were completed.

Frequently Asked Questions (FAQ)

Common questions about Alfospas (FAQ)

Q: What is the main purpose or medical use of Alfospas?

Alfospas is officially approved for the symptomatic treatment of pain associated with functional disorders of the digestive tract and biliary tract. Regulatory documents state that its primary use is to relieve the types of spasms (cramps) found in these areas.

Q: How quickly can a person expect Alfospas to start working?

According to official product information, the maximum concentration of Alfospas in the blood is typically reached between 1 and 2 hours after it is taken. This timeframe indicates when the active substance is most available in the body, which typically relates to the onset of effect, though individual response times can differ.

Q: Can Alfospas be taken on an empty stomach, or should it be taken with food?

Regulatory information indicates that Alfospas must be taken with sufficient fluid. Regulatory documents mention taking the tablet about 20 minutes before a meal. This timing is specified in the official instructions for use.

Q: What is the chemical name for the active ingredient in Alfospas?

The active ingredient in Alfospas is Alverine citrate. This substance is classified as a spasmolytic agent, according to the official product documents.

Q: What should be done if a dose of Alfospas is missed?

Official guidance states that taking a double dose to compensate for a missed one is not advised. The instructions indicate that the individual should simply take the next scheduled dose at the usual time and not exceed the maximum daily intake.

Q: Is Alfospas known to cause drowsiness or affect a person's ability to drive?

Based on safety data, Alfospas is not generally expected to affect the central nervous system or cause drowsiness. Official information reminds patients to observe their own reaction before engaging in activities like driving or operating machinery.

Q: How long should a course of Alfospas treatment typically last?

Regulatory documents do not specify a fixed duration for treatment, noting that the length of use depends on the symptoms being treated. For any extended period of use, regulatory information notes that ongoing treatment requires reassessment by a healthcare professional.

How should Alfospas be stored and disposed of?

Alfospas (Tiropramide Hydrochloride) must be stored and disposed of according to official regulatory specifications to maintain its stability and ensure safety.

Official Storage Conditions

Requirement Official Statement
Temperature Store in a cool place; specifically documented between mathbf2^circC and mathbf8^circC.
Protection Store in a dark and dry place; must be protected from both light and moisture.
Container Rule Keep the product in its original container/outer carton and ensure the container is tightly closed.
Handling Do not freeze the product, and avoid storage in high heat.
Child Safety Keep out of the sight and reach of children as a mandatory precaution.

Official Disposal Instructions

Unused or expired Alfospas must be disposed of in accordance with appropriate laws and regulations for pharmaceutical waste. Disposal must prevent the product from entering drains, other waterways, or soil.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Alfospas found in:

A-Z Index: